| Name | Title | Contact Details |
|---|---|---|
Matthew Burry |
Sr. Director of Information Security | Profile |
Chii-Ren Tsai |
Director, Global Information Security Architecture and Engineering | Profile |
Eberechi Ugwo-Amole |
Director - Information Security and Risk | Profile |
Cybrexa is a clinical-stage oncology biotechnology company developing novel antigen-independent peptide drug conjugates (ADCs) aimed at combatting a range of cancer types, including ovarian, breast and non-small cell lung cancer. With the potential to disrupt the standard of care, the Cybrexa alphalex™ technology is a novel antigen-independent peptide drug conjugate (PDC) platform that enables targeted delivery of highly potent anticancer treatments and aims to revolutionize the standard of care in oncology. The platform consists of a pHLIP® peptide, linker, and small molecule anti-cancer agent. pHLIP® peptides are a family of pH-Low Insertion Peptides that target acidic cell surfaces. pHLIP® was developed at Yale University and the University of Rhode Island, and is exclusively licensed to pHLIP, Inc. alphalex™ represents the disruptive next generation in tumor targeting. Early clinical trials of the company`s lead candidate, CBX-12, demonstrate robust efficacy signals and tolerability in patients with metastatic cancer. As a privately held company, Cybrexa is led by a management team experienced at building life science companies and driven by scientists with an expertise in drug development and oncology.
Be Biopharma is a leader in developing B cells as medicines, treating disease with the human body`s native protein factories. We precisely engineer B cells to harness their intrinsic drug-like properties – remarkable protein production, selective tissue targeting, and fine control of their cellular environment – to forge a new category of cell therapy. These medicines are designed to be durable, allogeneic, re-dosable, and administered without toxic conditioning, creating new avenues to halt or reverse severe diseases like cancer, autoimmune conditions, and enzyme deficiency. Founded by Longwood Fund and B cell engineering pioneers David Rawlings, M.D., and Richard James, Ph.D., Be Biopharma is re-imagining medicine based on the power of B cell therapy. Be Bio was founded in October 2020 by Longwood Fund with a $52 million Series A investment led by Atlas Ventures and RA Capital, joined by Alta Partners and Takeda Ventures.
Immunocellular Therapeutics Ltd (Fka: Optical Molecular Imaging Inc) is a Woodland Hills, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of infectious disease.
Kyverna Therapeutics is pioneering a new class of therapies and cures for serious autoimmune diseases. Our therapeutic platform combines advanced T cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the root cause of disease. Kyverna is venture-backed and located in the San Francisco East Bay.